Outcomes of retinal detachment surgeries in children with Stickler-syndrome

Session Details

Session Title: Quick Fire Free Paper Session

Session Date/Time: Saturday 17/02/2018 | 11:45-13:00

Paper Time: 12:10

Venue: Ballroom II & III.

First Author: : E.Maka HUNGARY

Co Author(s): :    G. Barcsay   M. Resch   Z. Recsan   A. Szabo   A. Papp                 

Abstract Details


To assess long-term outcomes 6-7 years after initiation of intensive anti-VEGF therapy in patients with exudative age-related macular degeneration (AMD).


Semmelweis University, Department of Ophthalmology, Bajcsy-Zsilinszky Hospital, Budapest


47 AMD patients originally treated with aflibercept or ranibizumab who participated in the “Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW 2)” phase 3 clinical trial were followed. We evaluated their best-corrected visual acuity (BCVA) on ETDRS charts and anatomic results on spectral-domain ocular coherence tomography (OCT), and fundus autofluorescence (FAF) 6-7 years after initiation of the anti-VEGF therapy.


Mean BCVA of the study eyes was 54±13 before entering the VIEW 2 trial. 82±5 months later, mean BCVA decreased to 45±25. 40 percent of the study eyes had 20/70 or better BCVA, with 17% achieving a BCVA of 20/40 or better. 36 percent of study eyes had a BCVA of 20/200 or worse. Compared with VIEW2 baseline measurements 38 percent of study eyes declined by 15 letters or more. Since the exit from the VIEW 2 trial, study eyes had received a mean of 2 anti-vascular endothelial growth factor (VEGF) injections during the mean 4.8 year interval. Active exudative disease was detected by spectral-domain OCT in 15% of study eyes. Macular atrophy was detected by FAF in 96% of eyes.


Approximately 5 years after intensive anti-VEGF treatment in the VIEW 2 trial, 40 percent of patients demonstrated good visual outcomes, whereas 38 percent had poor outcomes. Even at this late stage in the therapeutic course, exudative AMD patients remain at risk for substantial visual decline."

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy